Get the Stockscreener App
17.21
4.23%
-0.76
Pre-market:
17.38
0.17
+0.99%
Apellis Pharmaceuticals Inc stock is traded at $17.21, with a volume of 5.60M.
It is down -4.23% in the last 24 hours and down -22.76% over the past month.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
See More
Previous Close:
$17.97
Open:
$17.96
24h Volume:
5.60M
Relative Volume:
2.00
Market Cap:
$2.20B
Revenue:
$1.00B
Net Income/Loss:
$22.39M
P/E Ratio:
139.35
EPS:
0.1235
Net Cash Flow:
$45.01M
1W Performance:
-9.13%
1M Performance:
-22.76%
6M Performance:
-25.21%
1Y Performance:
-28.74%
1-Day Range:
$17.16
$18.09
1-Week Range:
$17.16
$19.36
52-Week Range:
$16.10
$30.48
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Name
Apellis Pharmaceuticals Inc
Sector
Industry
Phone
617-977-5700
Address
100 FIFTH AVENUE, WALTHAM, KY
Compare APLS vs VRTX, REGN, ALNY, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
17.21 | 2.20B | 1.00B | 22.39M | 45.01M | 0.1235 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-26 | Initiated | Roth Capital | Buy |
| Jan-28-26 | Initiated | Barclays | Equal Weight |
| Jan-21-26 | Upgrade | BofA Securities | Neutral → Buy |
| Nov-06-25 | Initiated | Wolfe Research | Peer Perform |
| Oct-15-25 | Initiated | Wells Fargo | Overweight |
| Sep-26-25 | Downgrade | Goldman | Neutral → Sell |
| May-09-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-09-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-21-24 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-25-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Oct-16-24 | Initiated | William Blair | Outperform |
| May-31-24 | Initiated | Piper Sandler | Neutral |
| Feb-05-24 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-09-23 | Initiated | Goldman | Buy |
| Nov-02-23 | Initiated | Mizuho | Neutral |
| Oct-06-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-29-23 | Reiterated | Citigroup | Buy |
| Aug-03-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-01-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-10-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-19-22 | Initiated | H.C. Wainwright | Buy |
| Jun-17-22 | Resumed | Stifel | Buy |
| Apr-14-22 | Downgrade | ROTH Capital | Neutral → Sell |
| Dec-08-21 | Initiated | Wells Fargo | Overweight |
| Nov-29-21 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-10-21 | Reiterated | BMO Capital Markets | Outperform |
| Sep-10-21 | Reiterated | Credit Suisse | Neutral |
| Sep-10-21 | Reiterated | Needham | Buy |
| Sep-10-21 | Reiterated | Oppenheimer | Outperform |
| Sep-10-21 | Downgrade | Wedbush | Outperform → Neutral |
| Aug-19-21 | Initiated | Jefferies | Buy |
| Aug-19-21 | Upgrade | Wedbush | Neutral → Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Apr-16-21 | Initiated | Goldman | Buy |
| Nov-19-20 | Initiated | Needham | Buy |
| Sep-01-20 | Initiated | Stifel | Buy |
| Jul-20-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Neutral |
| Apr-01-20 | Initiated | Raymond James | Strong Buy |
| Mar-31-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-11-20 | Upgrade | Wedbush | Underperform → Neutral |
| Jan-07-20 | Initiated | SVB Leerink | Mkt Perform |
| Dec-19-19 | Initiated | BofA/Merrill | Buy |
| Nov-22-19 | Initiated | Wedbush | Underperform |
| Nov-05-19 | Initiated | Credit Suisse | Neutral |
| Aug-01-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-30-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| May-24-18 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-12-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Apellis Pharmaceuticals Inc Stock (APLS) Latest News
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
Apellis wins new buy at Roth on Syfovre prospects - MSN
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Globe and Mail
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story - The Motley Fool
Apellis Pharmaceuticals, Inc. $APLS Holdings Cut by Hudson Bay Capital Management LP - MarketBeat
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart
BofA upgrades Apellis (APLS) to buy citing rapid Empaveli adoption and underappreciated kidney disease market potential - MSN
APLS: Cantor Fitzgerald Lowers Price Target While Maintaining Ov - GuruFocus
Cantor Fitzgerald Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Price-Driven Insight from (APLS) for Rule-Based Strategy - Stock Traders Daily
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift? - simplywall.st
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - The Chronicle-Journal
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion - Yahoo Finance
Integral Health Asset Management LLC Purchases Shares of 250,000 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Buy Rating Amid Growth P - GuruFocus
Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX) - The Globe and Mail
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31.0 - GuruFocus
Apellis stock wins new Buy at Roth on Syfovre (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm - MarketBeat
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Rhenman & Partners Asset Management AB Has $5.26 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds - The Globe and Mail
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve - Sahm
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS) - The Globe and Mail
(APLS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JP Morgan Raises Price Target for APLS, Maintains Overweight Rat - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
APLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors By Investing.com - Investing.com India
Apellis adds former Pfizer research chief to board By Investing.com - Investing.com Canada
Apellis Appoints Mikael Dolsten, M.D., Ph.D., To Board - citybiz
Apellis Pharmaceuticals Inc Stock (APLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):